Ishida K, Yamada K, Nishiyama R, Hashimoto T, Nishida I, Abe Y, Yasui M, Iwatsubo T: Glymphatic system clears extracellular tau and protect from tau aggregation and neurodegeneration. J Exp Med 219:e20211275, 2022

Kaneshiro N, Komai M, Imaoka R, Ikeda A, Kamikubo Y, Hashimoto T, Iwatsubo T, Sakurai T, Uehara T, Takasugi N: Lipid flippase dysfunction as a novel therapeutic target for endosomal anomalies in Alzheimer’s disease. iScience 25:103869, 2022

Sato K, Niimi Y, Mano T, Iwata A, Iwatsubo T: Automated evaluation of conventional clock-drawing test using deep neural network: potential as a mass screening tool to detect individuals with cognitive decline. Front Neurol 13:896403, 2022

Kasuga K, Kikuchi M, Tsukie T, Suzuki K, Ihara R, Iwata A, Hara N, Miyashita A, Kuwano R, Iwatsubo T, Ikeuchi T: Characterization of ATN profile classified using two different N markers in CSF. BMJ Neurol Open 4:e000321, 2022

Kishino Y, Matsukawa K, Matsumoto T, Wakabayashi T, Nonaka T, Kametani F, Hasegawa M, Hashimoto T, Iwatsubo T: Casein kinase 1d/e phosphorylates fused in sarcoma (FUS) and ameliorates FUS-mediated neurodegeneration. J Biol Chem 298: 102191, 2022

Sato K, Niimi Y, Mano T, Iwata A, Iwatsubo T: Time to onset of drug-induced parkinsonism: Analysis using a large Japanese adverse event self-reporting database. Biosci Trends 16:151-157, 2022

An H, Litscher G, Watanabe N, Wei W, Hashimoto T, Iwatsubo T, Buchman VL, Shelkovnikova T: ALS-linked cytoplasmic FUS assemblies are compositionally different from physiological stress granules and sequester hnRNPA3, a novel modifier of FUS toxicity. Neurobiol Dis 162:105585, 2022

Levine SZ, Goldberg Y, Yoshida K, Efthimiou O, Samara M, Cipriani A, Iwatsubo T, Leucht S, Furawaka TA: Early- and subsequent- response of cognitive functioning in Alzheimer’s disease: Individual-participant data from five pivotal randomized clinical trials of donepezil. J Psychiatr Res 148:159-164, 2022

Sato K, Niimi Y, Iwatsubo T, Ishii S: Change in long-term care service usage in Japan following the COVID-19 pandemic: a survey using a nationwide statistical summary in 2018–2021. Geriatr Gerontol Int 22:803-809, 2022

de Erausquin GA, Snyder HM, Brugha TS, Seshadri S, Carrillo M, Sagar R, Huang Y, Newton C, Tartaglia C, Teunissen C, Håkanson K, Akinyemi R, Prasad K, D’Avossa G, Gonzalez-Aleman G, Hosseini A, Vavougios GD, Sachdev P, Bankart J, Ole Mors NP, Lipton R, Katz M, Fox PT, Katshu MZ, Iyengar MS, Weinstein G, Sohrabi HR, Jenkins R, Stein DJ, Hugon J, Mavreas V, Blangero J, Cruchaga C, Krishna M, Wadoo O, Becerra R, Zwir I, Longstreth WT, Kroenenberg G, Edison P, Mukaetova-Ladinska E, Staufenberg E, Figueredo-Aguiar M, Yécora A, Vaca F, Zamponi HP, Lo Re V, Majid A, Sundarakumar J, Gonzalez HM, Geerlings MI, Skoog I, Salmoiraighi A, Boneschi FM, Patel VN, Santos JM, Arroyo GR, Moreno AC, Felix P, Gallo C, Arai H, Yamada M, Iwatsubo T, Sharma M, Chakraborty N, Ferreccio C, Akena D, Brayne C, Maestre G, Blangero SW, Brusco LI, Siddarth P, Hughes TM, Zuñiga AR, Kambeitz J, Laza AR, Allen N, Panos S, Merrill D, Ibáñez A, Tsuang D,Valishvili N, Shrestha S, Wang S, Padma V, Anstey KJ, Ravindrdanath V, Blennow K, Mullins P, Łojek E, Pria A, Mosley TH, Gowland PG, Girard TD, Bowtell R, Vahidy FS: Chronic neuropsychiatric sequelae of SARS-CoV2: Protocol 1 and methods from the Alzheimer’s Association Global Consortium. submitted to Alzheimers Dementia: Translational Research & Clinical Interventions 8:e12348, 2022

Poulakis K, Pereira JB, Muehlboeck J-S, Wahlund L-O, Smedby Ö, Volpe G, Masters CL, Ames D, Niimi Y, Iwatsubo T, Ferreira D, Westman E: Stage vs. Subtype hypothesis in Alzheimer’s disease: a multi-cohort and longitudinal Bayesian clustering study. Nat Commun 13:4566, 2022

Kazawa K, Akishita M, Ikeda M, Iwatsubo T, Ishii S: Experts’ perception of support for people with dementia and their families during the COVID-19 pandemic. Geriatr Gerontol Int 22:26-31, 2022

Haeberlein SB, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, Hansson O, Harrison K, von Hehn C, Iwatsubo T, Mallinckrodt C, Mummery CJ, Muralidharan KK, Nestorov I, Nisenbaum L, Rajagovindan R, Skordos L, Tian Y, van Dyck CH, Vellas B, Wu S, Zhu Y, Sandrock A: Two randomized phase 3 studies to evaluate aducanumab in early Alzheimer disease. J Prev Alzheimers Dis 9:197-210, 2022

Yoshida K, Seo M, Yan L, Sahker E, Cipriani A, Leucht S, Iwatsubo T, Efthimiou O, Furukawa TA: Personalized prediction of Alzheimer’s disease and its treatment effects by donepezil: an individual participant data meta-analysis of eight randomized controlled trials. J Alz Dis 89:1143-1157, 2022

Tsujikawa K, Hamanaka K, Riku Y, Hattori Y, Hara N, Iguchi Y, Ishigaki S, Hashizume A, Miyatake S, Mitsuhashi S, Miyazaki Y, Kataoka M, Jiayi L, Yasui K, Kuru S, Koike H, Kobayashi K, Sahara N, Ozaki N, Yoshida M, Kakita A, Saito Y, Iwasaki Y, Miyashita A, Iwatsubo T, Ikeuchi T, Miyata T, Sobue G, Matsumoto N, Sahashi K, Katsuno M: Actin-1 binding protein filamin-A drives tau aggregation and contributes to progressive supranuclear palsy pathology. Sci Adv 8:eabm5029, 2022

Rotstein A, Levine SZ, Samara M, Yoshida K, Goldberg Y, Cipriani A, Iwatsubo T, Leucht S, Furawaka TA: Cognitive impairment networks in Alzheimer’s disease: Analysis of three double-blind randomized, placebo-controlled, clinical trials of donepezil. Eur Neuropsychopharmacol 57:50-58, 2022